ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report released on Monday morning,Benzinga reports. They currently have a $23.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright boosted their target price on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. Jefferies Financial Group boosted their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Trading Up 8.9%

NASDAQ IBRX opened at $8.07 on Monday. The business’s 50-day moving average price is $7.57 and its 200 day moving average price is $4.17. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $12.43. The company has a market capitalization of $8.30 billion, a PE ratio of -21.24 and a beta of -0.03.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. Equities analysts predict that ImmunityBio will post -0.92 EPS for the current year.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Barry J. Simon sold 165,000 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. The trade was a 5.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 501,967 shares of company stock worth $4,466,412 in the last 90 days. 69.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently made changes to their positions in IBRX. Slow Capital Inc. purchased a new stake in ImmunityBio during the 3rd quarter worth $25,000. Envision Financial Planning LLC purchased a new position in ImmunityBio in the second quarter valued at about $28,000. Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio during the second quarter worth about $27,000. Truist Financial Corp acquired a new position in shares of ImmunityBio during the third quarter worth about $27,000. Finally, Swiss Life Asset Management Ltd purchased a new stake in shares of ImmunityBio in the third quarter worth about $27,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: China approval expands Anktiva’s global footprint — China granted approval for the Anktiva combination therapy for bladder cancer, marking the company’s first regulatory nod in Asia and broadening market reach to roughly 34 countries; this supports revenue potential and international commercialization. ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
• Positive Sentiment: Analyst backing and buy ratings — At least one firm has issued a Buy rating and some analysts publicly downplay the FDA letter’s long-term commercial impact, which can support short-term buying interest and help stabilize the share price. ImmunityBio Earns “Buy” Rating from D. Boral Capital
• Neutral Sentiment: Stock remains volatile since earnings — Commentary notes the stock is down materially since the last earnings report, reflecting heightened sensitivity to clinical/regulatory headlines and earnings-driven expectations for future profitability. Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
• Neutral Sentiment: Short-interest reporting is ambiguous — Public short-interest updates published this week are inconsistent/unclear; monitoring clear, confirmable short-interest data will help assess pressure from short sellers. (market data summaries)
• Negative Sentiment: FDA warning letter over Anktiva promotions — The FDA issued a warning saying a TV ad and a podcast contained false or misleading claims and inadequate risk disclosure, triggering a sharp intra-week sell-off and raising regulatory/compliance risk for the company. IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
• Negative Sentiment: Multiple investor lawsuits/investigations announced — Several law firms (Rosen Law, Kaplan Fox, Johnson Fistel, etc.) have announced investigations into potential securities claims tied to the company’s statements and promotional activity, increasing legal risk and potential liabilities. Rosen Law Firm Encourages ImmunityBio Investors to Inquire About Securities Class Action Investigation

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.